Guggenheim lowered the firm’s price target on Biogen (BIIB) to $165 from $168 and keeps a Buy rating on the shares. The firm, in its preview of Q1 earnings for 36 commercial-stage companies in its biotechnology coverage, revised some estimates to account for recent news flow, company commentary, and/or prescription trends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Morning Movers: Pharmaceuticals sink as impending tariffs seen coming
- Biogen price target lowered to $152 from $157 at Morgan Stanley
- Biogen cut to Hold at Argus on expected earnings decline
- Biogen downgraded to Hold from Buy at Argus
- Biogen announces U.S. FDA granted Fast Track designation to BIIB080